Meningioma other diagnostic studies

Jump to navigation Jump to search

Meningioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningioma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningioma other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningioma other diagnostic studies

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningioma other diagnostic studies

CDC on Meningioma other diagnostic studies

Meningioma other diagnostic studies in the news

Blogs on Meningioma other diagnostic studies

Directions to Hospitals Treating Meningioma

Risk calculators and risk factors for Meningioma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2] Haytham Allaham, M.D. [3]

Overview

Bromodeoxyuridine labeling study may be helpful in the diagnosis of meningioma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of meningioma and a greater incidence of recurrence following surgical resection.

Other Diagnostic Studies

Bromodeoxyuridine Labeling Study

Bromodeoxyuridine labeling study may be helpful in the diagnosis of meningioma. An elevated bromodeoxyuridine labeling index of meningioma is associated with:[1]

  • Rapid growth rate of the tumor
  • Greater incidence of recurrence following surgical resection of the tumor

References

  1. Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB (1990). "Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence". Acta Neuropathol. 80 (3): 311–7. PMID 2399811.